Table of Contents Author Guidelines Submit a Manuscript
Prostate Cancer
Volume 2011, Article ID 301850, 7 pages
http://dx.doi.org/10.1155/2011/301850
Research Article

Proliferative Tumor Doubling Times of Prostatic Carcinoma

1Department of Pathology, University of Colorado Anschutz Medical Campus, P.O. Box 6511, Aurora, CO 80045, USA
2Medical Oncology, University of Colorado Anschutz Medical Campus, CO 80045, USA
3Radiation Oncology, University of Colorado Anschutz Medical Campus, CO 80045, USA
4Pharmacy Department, University of Colorado Anschutz Medical Campus, CO 80045, USA

Received 1 April 2011; Accepted 4 July 2011

Academic Editor: Kenneth A. Iczkowski

Copyright © 2011 Priya N. Werahera et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, R. Siegel, J. Xu, and E. Ward, “Cancer statistics, 2010,” CA Cancer Journal for Clinicians, vol. 60, no. 5, pp. 277–300, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. G. J. Miller and J. M. Cygan, “Morphology of prostate cancer: the effects of multifocality on histological grade, tumor volume and capsule penetration,” Journal of Urology, vol. 152, no. 5, pp. 1709–1713, 1994. View at Google Scholar · View at Scopus
  3. W. A. Sakr, D. J. Grignon, J. D. Crissman et al., “High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20–69: an autopsy study of 249 cases,” In Vivo, vol. 8, no. 3, pp. 439–443, 1994. View at Google Scholar · View at Scopus
  4. E. D. Crawford, D. Hirano, P. N. Werahera et al., “Computer modeling of prostate biopsy: tumor size and location—not clinical significance—determine cancer detection,” Journal of Urology, vol. 159, no. 4, pp. 1260–1264, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Hirano, P. N. Werahera, E. D. Crawford, M. S. Lucia, E. P. DeAntoni, and G. J. Miller, “Morphological analysis and classification of latent prostate cancer using a 3-dimensional computer algorithm: Analysis of tumor volume, grade, tumor doubling time and life expectancy,” Journal of Urology, vol. 159, no. 4, pp. 1265–1269, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. D. F. Gleason, G. T. Mellinger, and L. J. Ardving, “Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging,” Journal of Urology, vol. 111, no. 1, pp. 58–64, 1974. View at Google Scholar · View at Scopus
  7. D. S. Coffey and J. T. Isaacs, “Prostate tumor biology and cell kinetics—theory,” Urology, vol. 17, no. 3, pp. 40–53, 1981. View at Google Scholar · View at Scopus
  8. D. M. Berney, “Biomarkers for prostate cancer detection and progression: beyond prostate-specific antigen,” Drug News and Perspectives, vol. 23, no. 3, pp. 185–194, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. A. C. Begg, N. J. McNally, D. C. Shrieve, and H. Karcher, “A method to measure the duration of DNA synthesis and the potential doubling time from a single sample,” Cytometry, vol. 6, no. 6, pp. 620–626, 1985. View at Google Scholar · View at Scopus
  10. R. Nemoto, K. Uchida, T. Shimazui, K. Hattori, K. Koiso, and M. Harada, “Immunocytochemical demonstration of S phase cells by anti-bromodeoxyuridine monoclonal antibody in human prostate adenocarcinoma,” Journal of Urology, vol. 141, no. 2, pp. 337–340, 1989. View at Google Scholar · View at Scopus
  11. K. M. G. Haustermans, I. Hofland, P. H. Van Poppel et al., “Cell kinetic measurements in prostate cancer,” International Journal of Radiation Oncology Biology Physics, vol. 37, no. 5, pp. 1067–1070, 1997. View at Publisher · View at Google Scholar · View at Scopus
  12. G. J. Miller and J. M. Cygan, “Diagnostic correlations with whole mounts of radical prostatectomy specimens,” Monographs in Pathology, no. 34, pp. 183–197, 1992. View at Google Scholar · View at Scopus
  13. D. F. Gleason, “Histologic grading and clinical staging of prostatic carcinoma,” in Urologic Pathology: The Prostate, M. D. Tannenbaum, Ed., pp. 171–198, Lea & Febiger, Philadelphia, Pa, USA, 1977. View at Google Scholar
  14. P. N. Werahera, G. J. Miller, K. Torkko et al., “Biomorphometric analysis of human prostatic carcinoma by using three-dimensional computer models,” Human Pathology, vol. 35, no. 7, pp. 798–807, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Nagao, Y. Yamamoto, T Hara et al., “Ki67 and BUBR1 may discriminate clinically insignificant prostate cancer in the PSA range <4?ng/ml,” Japanese Journal of Clinical Oncology, vol. 41, pp. 555–564, 2011. View at Google Scholar
  16. R. S. Svatek, M. Shulman, P. K. Choudhary, and E. Benaim, “Critical analysis of prostate-specific antigen doubling time calculation methodology,” Cancer, vol. 106, no. 5, pp. 1047–1053, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. H. P. Schmid, J. E. McNeal, and T. A. Stamey, “Clinical observations on the doubling time of prostate cancer,” European Urology, vol. 23, no. 2, pp. 60–63, 1993. View at Google Scholar · View at Scopus
  18. H. P. Schmid, J. E. McNeal, and T. A. Stamey, “Observations on the doubling time of prostate cancer: the use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume,” Cancer, vol. 71, no. 6, pp. 2031–2040, 1993. View at Google Scholar · View at Scopus
  19. M. S. Lucia, A. K. Darke, P. J. Goodman et al., “Pathologic characteristics of cancers detected in the prostate cancer prevention trial: implications for prostate cancer detection and chemoprevention,” Cancer Prevention Research, vol. 1, no. 3, pp. 167–173, 2008. View at Publisher · View at Google Scholar · View at Scopus